Binge Eating Liraglutide Intervention

PHASE3TerminatedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 29, 2017

Primary Completion Date

September 30, 2019

Study Completion Date

October 1, 2019

Conditions
Binge-Eating Disorder
Interventions
DRUG

Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml

subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg (6 mg/mL, 3 mL). Matching the recommended dosage and administration guidelines of the FDA-approved labeling for the use of liraglutide (Saxenda), the medication will be initiated at 0.6 mg daily for 1 week, and then increased by 0.6 mg/day in weekly intervals until a dose of 3.0 mg/day is achieved.

DRUG

Placebo

subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg (6 mg/mL, 3 mL). It is designed to be identical to the pen used for liraglutide (Saxenda). Placebo product inactive ingredients: disodium phosphate dihydrate, 1.42 mg; propylene glycol, 14 mg; phenol, 5.5 mg; and water for injection

Trial Locations (1)

19140

University of Pennyslvania, Philadelphia

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novo Nordisk A/S

INDUSTRY

lead

Kelly Allison

OTHER

NCT03279731 - Binge Eating Liraglutide Intervention | Biotech Hunter | Biotech Hunter